Stugeron is a piperazine calcium channel blockers, belonging to the peripheral vasodilator. It is white or white-like crystal or crystalline powder. It is odorless and almost tasteless. It is insoluble in water, soluble in boiling ethanol and easily soluble in chloroform or benzene. Stugeron has dilatation effect on the vascular smooth muscle and has antagonism effect on various kinds of vasoconstrictor substances such as serotonin, epinephrine, bradykinin and vasopressin, etc., it can ease the vasospasm. Its antispasmodic effect is stronger than papaverine with a not obvious sedative effect. This product can enables a significant increase in the cerebral blood flow and can significantly improve the cerebral circulation and coronary circulation with longer duration of action and has inhibitory effect on various kinds of vasoactive substances. It is capable of relieving vasospasm and preventing the embrittlement of the blood vessel. In the situation of not affecting heart rate and oxygen consumption, it can increase the coronary blood flow and cardiac output. Intravenous injection of this product can cause short period of blood pressure drop while oral administration has no such effect. In addition, this product also has effect on preventing embrittlement of the blood vessel as well as anti-histamine effect.
It will onset within 30 minutes after oral administration with the plasma concentration reaching peak within 3-7 hours. The effect can last for four hours with the half-life of plasma concentration being 3 to 24 hours.
Clinically Stugeron is mainly used for the treatment of peripheral vascular disease and cerebrovascular disorders such as cerebral embolism, cerebral thrombosis, cerebral arteriosclerosis and hypertension induced circulation insufficiency, cerebral hemorrhage, subarachnoid hemorrhage convalescence and sequelae of traumatic brain injury. It also has efficacy in treating the mental neuropathy and coronary sclerosis. It can also be used for treating the inner ear vertigo and nausea, vomiting and motion sickness caused by other disorders.
The main adverse reactions of Stugeron: occasionally drowsiness, rash, gastrointestinal reactions, dizziness, fever or flu, intravenous blood pressure can cause short-term decline of the blood pressure; pregnant women should take with caution; patients of intracranial hemorrhage and acute cerebral infarction should be hanged.
The above information is edited by the Chemicalbook of Dai Xiongfeng.

It is long-efficacy, multifunction vasoconstriction antagonists. It can dilate blood vessels, improve blood circulation and prevent blood vessel embrittlement. It can be used in the treatment of cerebral vascular diseases as well as has efficacy in treating cervical vertigo caused headaches, dizziness, insomnia, memory loss, paralysis, numbness, weakness and slurred speech embolism.

It can be produced through: first use anhydrous piperazine and brominated diphenyl methane for preparation of benzhydryl piperazine, then condense with chlorine allyl benzene to obtain it. Diphenyl methane was heated in the light, add bromine and incubate for 1h at 130 ℃ which generates brominated diphenyl methane, C13H11Br, [776-74-9] with the melting point of 45 ℃. Add the brominated diphenyl methane drop wise into the piperazine toluene and stir for 3h at 80-90 ℃, further wash with water after cooling, then use 10% dilute hydrochloric acid for extraction; The acid layer was basified for being precipitated, filtered and dried to give benzhydryl piperazine. Dissolve it in 95% ethanol, add sodium carbonate and add drop wise of allyl benzene at about 65 ℃, after the completion of the dropping, heat and reflux for 4h, filter hot and the filtrate was left overnight for precipitate the crystalline, filter to get the crude product of Stugeron which under refinement become finished product with melting point of 117-119 ℃. In terms of diphenyl methane, the total yield is 48.2%.